Imagine if you could choose your agency partners based on attributes most appealing to you. With a swipe to the right or left, you could secure them a roster position or doom them to languish in procurement.
Celebrity success or fail? Here's what the American Lung Association, Pfizer and Tim Daly likely did not see coming when they joined forces to raise awareness about pneumococcal pneumonia.
Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog
Health economic and outcomes research datasets have rarely been integral to product development and communication plans.
The Ketchum veteran joined the nonprofit healthcare system in mid-2014.
A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."
Burcin's charge is to keep momentum going at the indie agency, known for placing ice-cream carts outside of rival agencies and other recruiting tactics.
Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet
Recent polls paint a mixed picture of physicians' willingness to see pharma sales reps. What gives? Are no-see docs up or down, and what's behind the dissonant findings?
After Bill McEllen's departure, the company promoted Mark Willmann to lead the agency.
FitzPatrick is departing the company as it evaluates its 150 agency partnerships.
Now that payers are locking in discounts at launch from drugmakers, where do co-pay cards fit in the marketing mix?
A pharma research forefather. An agency builder. A "guy you wanted in the room." These Medical Advertising Hall of Fame inductees are a professionally diverse and richly worthy trio.
Seven potential blockbusters set to launch in 2016; Amarin case may lead to 'misleading' marketing; Valeant, Turing raised prices to meet preset targets
The idea that 30 days is enough time for the FDA to evaluate anything is, of course, quite silly. But Sen. Cruz takes it one step further.
Click for an infographic to learn more about orphan drugs, rare diseases and the top-selling drugs in the category.
Gleevec generics hit shelves; four OxyContin patents are invalidated; Sanofi axes 600 positions
Plus other industry hires and changes
Here are some compelling campaigns that invoke a visceral response—you laugh, cry, even cringe—followed by a more thoughtful and inspired reaction to learn more.
AbbVie cuts 2016 sales estimate for Viekira Pak; Abbott to acquire Alere for $5.8 billion; Express Scripts to stop covering Valeant's Glumetza
It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.
We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.
DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.
The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.
The Silicon Valley gadget guru who helped define the beyond-the-pill era will talk about embedding nontraditional capabilities into biopharma business models.
The drugmaker's CEO said the campaign helps dispel pessimism created from a history of cancer drugs that lack "significant value."
FDA approves Merck's HCV doublet regimen; Gilead CEO steps down; Clinton takes aim at Valeant price hikes
Curating personal relationships is one of the most valuable functions medical marketers can provide. The best way is through face-to-face interaction.
In many cases, the drug required physicians to request prior authorization.
Sales of cystic-fibrosis drug Orkambi higher than expected; new sensor tracks sweat; J&J develops clinical trial to find new way to treat depression
The traditional line of attack is genuine and requires little in the way of spin—yet still, every time a Turing rears its head, it gets blown back in small and indigestible pieces.
Biogen execs said a recently launched DTC campaign for Tecfidera is showing positive early signs.
Former Biosector 2 US MD Jeanine O'Kane was named inVentiv Health PR Group's US MD.
The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.
The FDA plans to release new guidance on advertising in 2016; Trump supports Medicare price negotiations; Novartis CEO: golden days of drug pricing are over
Prior to Medicines360's arrival on the scene, there were only three IUDs on the market. The lack of competition drove prices sky-high.
Faced with slowing sales, the company is in the early stages of developing value-added services that support better patient outcomes.
Following November pitch, WPP agency will handle digital strategy, creative and social in region.
Sanofi is the category leader. Its product, Lantus Solostar, brought in $5.27 billion in US sales between October 2014 and September 2015.
New entrants in the type 2 diabetes treatment market share a similar goal: To solve patients' constant struggle with glycemic control.
Experts insist that R&D efforts in the category must mirror educational campaigns and lifestyle changes, and quickly.
The FDA accepts bid for new label for Jardiance; Markey puts on a hold on Califf's FDA nomination; GSK is studying the Zika virus
Valeant CEO is recovering; three drugmakers partner for early-stage cancer research
Michel Murino, former CEO of southern Europe and France, will now head the company's regional operations in Europe.
If we don't clean up our act and do something about predatory pricing scandals, we'll wind up with Washington bureaucrats telling us what we can charge for our products.
NICE recommends Opdivo for skin cancer; Sanofi layoffs could be looming; Senators ask for feedback on Sovaldi investigation
The Office of Prescription Drug Promotion said Pfizer subsidiary Hospira omitted information and misbranded the drug
"A global launch of a type-2 diabetes drug. It was a four-year trail of cheers and tears."
The agency named a new chief strategist and creative director along with new leads for its Minnesota, Chicago and New York healthcare practices.
GSK CEO says consumer health business could be its own entity; regulatory setbacks cloud future of DMD treatments; OPDP slams YouTube video
If we were going to be one of a kind, we needed a staff that understood and had lived through what our clients were facing.
Part of drugmakers' sales growth stems from price increases; AbbVie's Venetoclax gets second Breakthrough designation; two states in India stop Avastin sales
We love smart stuff. Smartwatches track our daily activity, smart fabrics monitor vital signs, smart shoes navigate our journeys and smart drugs boost cognitive functioning.
They will attempt to develop a new industry standard for digital advertising viewability, a much debated topic that has vexed the broader advertising industry.
Pinnacle Health Communications and Franklyn Healthcom merge to offer "more complete" customer-centric solutions.
Government pressure can influence drug-pricing decisions; Samsung's biosimilar version of Enbrel is approved in Europe; J&J to cut jobs in medical-devices business
While DTC advertising does significantly impact consumer demand, most evidence suggests the majority of this demand benefits the overall state of consumer health.
Part of LinkedIn's appeal lies in the high level of engagement of its members and the potential for precise targeting of content and talent searches.
The FDA declines to approve two drugs for Duchenne muscular dystrophy; government watchdog questions FDA's post-market drug tracking; WebMD denies acquisition talks
Summit Partners' investment in the health information site expected to aid the company's efforts to compete with sites like WebMD
Drugmakers seeking to develop "beyond-the-pill" digital initiatives have to be willing to engage patients in new ways, McKinsey & Company report finds.
Spurgeon on finding simplicity in Procter & Gamble's "The Boy Raised by Goats" and a moving campaign about disabilities.
Valeant is "uncertain" when CEO will return; Bayer hires Razorfish and iCrossing for digital; more drugmakers that sell hemophilia drugs are hiring patients
Life-sciences companies often behave as though focusing on patient needs is simply a matter of asking, "How can we provide patients with more services?
The kits aren't likely to enhance American Girl's bottom line in any significant way, yet the flood of press coverage painted the company as compassionate in a way that few such organizations are.
Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup
Many of the characters we are now meeting do not appear to be directed at a patient insight or purposefully used to de-stigmatize a disease.
The healthcare agency debuts with Swedish-based pharma company Orexo as its first client.
Two senators, including presidential candidate Bernie Sanders, threatened to hold up his nomination.
The FDA in November approved three new drugs that treat the rare blood cancer.
HCPs sound off on CMS opioid proposal; Senate committee to decide if Califf gets FDA commissioner nod; Celgene names new CEO
It is worth noting that the FDA sent only nine warning letters last year, all focused on well-recognized violations, such as minimization of risk information and unsubstantiated claims.
Mazzola says healthcare advertising is having a watershed moment.
Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed
The digital health sector brought in an estimated $6 billion in funding in 2015.
Damian Braga, who held the role previously, retired after 27 years working for the drugmaker
GSK will stop using outside doctors to promote its drugs; Roche will file its immuno-oncology drug for approval; Mylan inks deal to develop six biosimilars
Fitbit faces allegations of inaccurate heart monitoring; Viiv Healthcare to collaborate with Janssen; Guardant Health raises funding for its cancer blood tests
Nashville-based ReviveHealth posted $8.7 million in revenue in 2014.
Millennials at pharma agencies are driven and tech-savvy but also pay too much attention to promotion and the shape of their careers, say agency leaders.
The drugmaker led a Series C fundraising round totaling $175 million. The funding will be used to accelerate clinical trials.
Lilly's Jardiance starting to gain market share; Merck "raring" to make acquisitions; Sanofi said it will stop marketing Afrezza
Sanofi spent $3.75 million on advertising for Afrezza in the third quarter of 2015 yet the therapy only brought in about $2 million in revenue.
The American Association of Advertising Agencies said stopping calls for a ban on DTC is a top agenda item for the trade group in 2016.
Gilead's hep-C combo gets Breakthrough designation; Baxalta licences experimental cancer drugs; Novartis agrees to settle class-action lawsuit
As students, about 27% of MM&M's healthcare transformers received degrees in subjects that did not include health, business or technology.
A Q&A with Sandra Carey, president of the McCann Pharmacy Initiative, on the move to push pharmacy to the forefront.
The FDA approved 45 new drugs in 2015; Baxalta signs immuno-oncology deal; pharma M&A activity may slow this year
FCB Health opted to merge the two agencies and rebrand their US shops, which together plan to fill 40 open positions in 2016.
Ryan Olohan, National industry director, healthcare, Google
Halle Tecco, Managing director, Rock Health
Dr. Robert Wachter, Professor, chief of the division of hospital medicine, University of California, San Francisco
Ruchin Kansal, Executive director and head, business innovation, Boehringer Ingelheim
Aschkan Abdul Malek, CEO/co-founder, AlemHealth
Walter De Brouwer, Founder and CEO, Scanadu
Stephanie Bova, Senior director, Takeda Digital Accelerator, Takeda
Meg Columbia-Walsh, Global lead, digital healthcare, Cognizant
Entrepreneur in residence, Martin Trust Center for MIT
Michael Vinegar, director, medical e-strategy, Novartis
Sandra Elliott, VP, consumer technology and service development, Meridian Health